Dimurocan 150 mg (Fluconazole)

Adult dose

The route of administration should be determined according to the patient's clinical condition. Because oral formulations are rapidly and almost completely absorbed, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. ○ Adults 1. Vaginal candidiasis: Administer a single oral dose of 150 mg of fluconazole. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this medicine is 400 mg once on the first day, followed by 200 mg once daily from the next day; the dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment is determined by clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this medicine is 400 mg once on the first day, followed by 200-400 mg once daily from the next day. The duration of treatment is determined by clinical and mycological response, but treatment should usually continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg of this medicine once daily indefinitely after the patient has completed all initial treatment. 5. Prevention of fungal infections in immunocompromised patients at risk due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this medicine once daily, depending on the patient's level of risk for fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infections, such as bone marrow transplant recipients with severe or expected prolonged neutropenia. In such patients, administer 400 mg starting 5-6 days before the onset of neutropenia is expected, and continue administering 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or more. 6. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails have regrown (until new, uninfected nails have grown). It usually takes 3-6 months for a new fingernail to grow and approximately 6-12 months for a toenail; growth rates may vary by individual and age. Even after successful long-term treatment, the fingernails or toenails may sometimes remain damaged. For skin fungal infections, including athlete's foot (tinea pedis), tinea corporis, jock itch (tinea cruris), and cutaneous candidiasis: The usual dose of this medicine is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, athlete's foot may require treatment for 6 weeks depending on its course. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. ○ Elderly patients If renal function is normal, the usual adult dose is administered. In patients with renal impairment (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. ○ Patients with renal impairment This medicine is excreted mainly in the urine unchanged. No dose adjustment is necessary for a single dose; however, when multiple doses are required, administer the usual dose only on the first day and adjust the dose from the next day as follows: Creatinine clearance (mL/min) > 50: 100% of the usual dose Creatinine clearance (mL/min) ≤50 (not on dialysis): 50% of the usual dose Patients on hemodialysis: 100% of the usual dose after each hemodialysis session Patients receiving hemodialysis should receive 100% of the usual dose after each hemodialysis session. On non-dialysis days, administer a reduced dose according to creatinine clearance.

This medication should not be administered to certain patients. Patients who have had allergic reactions to this medication or other similar drugs, pregnant women or women who may become pregnant, and nursing mothers should not take this medication. Furthermore, patients taking certain medications should avoid co-administration with this drug, especially with medications that may affect the heart. Patients with lactose intolerance or certain genetic issues should also refrain from taking this drug. Before taking this medication, patients must verify their allergy history, kidney and liver function status, and any heart diseases. Since this drug may affect the electrical activity of the heart, patients at risk for arrhythmia should be particularly cautious. While this medication is generally well tolerated, rare adverse reactions may occur in various organs such as the blood, liver, and kidneys, necessitating regular monitoring during treatment. If skin rashes or allergic reactions occur, medical consultation should be sought immediately. This medication can interact with various drugs, so patients taking other medications must inform their healthcare provider, particularly when co-administering with heart medications, anticoagulants, antidepressants, immunosuppressants, and analgesics. Pregnant or reproductive-age women should ensure effective contraception during and for a certain period after taking this medication and its use among pregnant women is not recommended. Nursing mothers should also avoid taking this medication. The safety and efficacy of this medication have not been fully established in infants or children, so it should be used cautiously and only when necessary. Care should be taken when driving or operating machinery, as this medication may cause dizziness or seizures. Lastly, in the event of an overdose, hallucinations or unusual behavior may occur, requiring immediate medical attention. This drug is mainly eliminated through urine, so blood dialysis may be beneficial in cases of overdose.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, taste disturbance, tremor, vertigo, Torsades de Pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, increased ALT, increased AST, increased serum alkaline phosphatase, cholestasis, jaundice, increased bilirubin, hepatotoxicity, liver failure, hepatocellular necrosis, hepatitis, hepatocellular damage, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial swelling, hair loss, drug reactions with eosinophilia and systemic symptoms, myalgia, fatigue, malaise, asthenia, fever, adrenal insufficiency, hallucinations, altered behavior

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain the storage temperature between 1 to 30 degrees Celsius to safely retain its efficacy.

Appearance

Pink rectangular tablets

Package unit

30 tablets/bottle